Summarized by Masters of Longevity from PR Newswire.
A phase 2 trial found tofacitinib reduced immune overactivity and improved skin conditions.

Key Takeaways
- Tofacitinib reduced interferon-driven immune signaling in participants.
- Tofacitinib improved hidradenitis suppurativa and alopecia areata scores.
- Causal neurological benefits were not proven without placebo controls.



